制药业发展新方向

新加坡——

对制药业来说,过去的十年充满着挑战。随着大量药物专利保护的到期,新药物研发规划的停滞,以及来自非专利制药公司的加剧竞争,老牌制药厂商已经损失惨重。

如今,传统市场已趋饱和。工业化国家的残酷现实——包括由于人口老龄化对于医疗保险模式的挑战,这些医疗保险模式以税收和雇员医疗公积金为经费来源——迫使政府采取更加经济,符合真实价值的透明药物价格体系的管理制度。

To continue reading, please log in or enter your email address.

To continue reading, please log in or register now. After entering your email, you'll have access to two free articles every month. For unlimited access to Project Syndicate, subscribe now.

required

By proceeding, you are agreeing to our Terms and Conditions.

Log in

http://prosyn.org/fPCFW1f/zh;

Cookies and Privacy

We use cookies to improve your experience on our website. To find out more, read our updated cookie policy and privacy policy.